HEALTH● LOW1h ago · Sep 2, 2026, 9:15 PM
INVENTIVA : Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH
finanznachrichten.de · Germany · western europe
Inventiva announced the final patient visit in its Phase 3 clinical trial for Lanifibranor, a key development in its research for MASH treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH42m agoSummit Therapeutics in focus as its lung cancer drug shows survival benefitSeeking Alpha TechHEALTH1h agoChildren return to school in DR Congo amid growing concerns over EbolaAl Jazeera [en]HEALTH1h agoMedical groups offer vaccine guidance to fill federal vacuumredriverradio.org · United StatesHEALTH2h agoWomen health innovators face arduous path to successnynganobserver.com.au · Australia